Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
Martin Borch Jensen Profile picture
@MartinBJensen
Apr 17, 2020 • 3 tweets • 2 min read • Read on X
#SciTwitter Does anyone know how often #receptors or #ligands are the limiting factor for in vivo signaling pathways? Versus equilibrium where modulating either side even a little affects activity.
@keiser_lab @kevansf @srikosuri
For posterity: As far as I can tell so far, when receptors are expressed constitutively at decent levels, ligands are usually limiting. Receptors that are conditionally expressed are usually limiting. Haven't figured out how hard 'limiting' applies in either case.
This is from conversations rather than primary research, so #CaveatEmptor.

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with Martin Borch Jensen

Martin Borch Jensen Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MartinBJensen

Martin Borch Jensen Profile picture
Mar 31
I'm struggling to wrap my head around the new Weissman lab myHSC depletion paper:
The first authors don't seem to be on twitter but hoping I can crowdsource a fun discussion. @dbgoodman @ImmunoFever @Jeff_Mold @Satpathology @CalebLareau...nature.com/articles/s4158…
The premise of the paper is that immune function declines with age in part because a haematopoetic stem cell (HSC) population skewed towards myeloid lineage increases in prevalence, and that targeting this population with antibodies can restore function. Cool idea!
❓1⃣: How well defined are myHSCs?
Here myHSC seems to be defined as CD150 high, based mainly on Beerman 2010 .
But looking at Figure 3, CD150 expression is a continuous distribution. Is this a clear cell population with somewhat understood behavior? pnas.org/doi/full/10.10…
Image
Read 11 tweets
Martin Borch Jensen Profile picture
Jul 5, 2022
If you want to build a career in biotech, should you get a PhD after college or join a company directly (as a Research Associate/RA, usually)?
There's no single answer, but I have the conversation often enough that I thought I'd share some pros/cons... (1/n)
First, see this thread about different types of biopharma companies. For reasons I'll get into, I think early stage (probably founder led) biotech is your best bet unless you still want to do PhD later.
(PS if you want to be a professor, it's 💯 PhD) 2/n
PhD will give you more options.
Some companies (incl. @GordianBio) will help you grow from RA to Scientist role (and beyond). But many, esp larger, companies have a glass ceiling if you don't have a PhD. Even if you pick one w/o glass ceiling, you'll be worse off it if fails. 3/n
Read 13 tweets
Martin Borch Jensen Profile picture
Jul 3, 2022
All these points resonate, for early stage biotech at least. @erlichya touches on this, but I think worth separating "industry" into different clusters that will feel quite different to someone coming from academia (still oversimplified, of course):
Pharma (eg Pfizer) vs biotech:
You wear fewer hats, see less of the company but company as a whole spans wider range of expertise, fewer changes in direction, often higher income but no chance of getting rich. Both have job insecurity: pharma doesn't go die but programs do.
Clinical vs R&D stage biotech:
Clinical may still have R&D but it's no longer the biggest driver of success vs failure. Assay validation/rigor > assay development/invention. Clinical can feel more like pharma, but with more urgency/stakes: one program = life or death of co.
Read 7 tweets
Martin Borch Jensen Profile picture
Jan 24, 2022
#SciTwitter After a lot of research and asking around, I'm making the lab equipment recommendations 🧵 I wish I'd had 2 months ago. RT/share with a #newPI or startup 🔬⚗️🛒
Note, much of the equipment hasn't arrived yet, will add comments after actual use.
-80 #freezer
Two clear winners: PHC (@panasonic) and Stirling Ultracold. Both low energy, quiet, reliable. We went with PHC because I know those to last many years, and slightly cheaper.
Thanks @MarcoJost_ @letUbeU @aryelipman #MBCBiolabs
-20 #freezer
Less clear, many viable options. We ended up getting a split of PHC MDF -30 (recommended as quieter) and much cheaper Corepoint Scientific/@VWR, will see which we prefer. Thermo hasn't failed #MBCbiolabs, but $$$ and several people said poor customer support.
Read 14 tweets
Martin Borch Jensen Profile picture
Jan 5, 2022
Something is changing about how scientific research is funded.

@Jasonmmast @endpts covers a growing set of science funding experiments: endpts.com/inside-the-mul…
These include high-throughput grants (e.g. #Fast, #Impetus), new institutes (@ArcadiaScience, @AltosLabs, @arcinstitute... I guess A is for new beginnings?), and new structures like 'nonprofit startups' (@Convergent_FROs) & @newscienceorg.
As with all experiments, I expect that some of these will disappear and that others will be a central part of science in ten years.
But them happening at all is enough to renew a conversation about how science is funded and conducted.
Read 9 tweets
Martin Borch Jensen Profile picture
Dec 27, 2021
💸 98 Longevity Impetus Grants were awarded in 2021, thanks to generous donations from @juanbenet @jamesfickel @VitalikButerin @JedMcCaleb @KarlPfleger @FEhrsam and 1 anonymous donor.
I'll summarize outcomes in this thread, awardees listed in prior one:
🦸🏽 While I've been doing most of the tweeting, the Longevity Apprentices @LNuzhna @kush__sharma @edmarferreira & Tara Mei are the real heroes for running the operations.
This has been a great Apprenticeship project, merging action and exposure to research
martinborchjensen.com/apprenticeship
🚅 The review + awards process was fairly smooth, thanks in part to @kush__sharma's custom reviewer UI. Several reviewers told us unprompted that it was their best review experience ever; the UI took 2 wks to make, so there's low hanging fruit for other agencies in that area.
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

Send Email!

:(